Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43174

UPID:
CP26A_HUMAN

ALTERNATIVE NAMES:
Cytochrome P450 retinoic acid-inactivating 1; Retinoic acid 4-hydroxylase; Retinoic acid-metabolizing cytochrome

ALTERNATIVE UPACC:
O43174; B3KNI4; Q5VXH9; Q5VXI0

BACKGROUND:
The enzyme Cytochrome P450 26A1, known for its alternative names such as Retinoic acid-metabolizing cytochrome, is integral to the metabolism of vitamin A derivatives. It ensures the proper regulation of retinoic acid signaling, a key pathway in cellular differentiation and development, by hydroxylating active isomers of retinoic acid, including all-trans-retinoic acid, thereby limiting their biological activity.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cytochrome P450 26A1's function offers a promising avenue for developing novel therapeutic approaches. Its critical role in managing retinoic acid activity highlights its potential impact on treating diseases associated with retinoic acid dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.